

PART - I

BLISS GVS PHARMA LIMITED

CIN: L24230MH1984PLC034771

Regd. Office: 102, Hyde Park, Sakivihar Road, Andheri (East), Mumbai - 400 072.

(Rs. in Lacs)

Consolidated Half Year Ended FY 16 Operating Revenue at ₹ 270.95 cr

Standalone Half Year Ended FY 16 Operating Revenue at ₹ 173.91 cr Consolidated Half Year Ended FY 16
PBT at ₹ 74.05 cr

Standalone Half Year Ended FY 16
PBT at ₹ 59.40 cr

Note: The aforesaid highlights are a compilation of consolidated financials and other information all of which have not been audited.

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30.09.2015

				STAND	ALONE			
R.	PARTICULARS	QUARTER ENDED			HALF YEAR ENDED		YEAR ENDED	
lo.		30.09.2015 (UNAUDITED)	30.06.2015 (UNAUDITED)	30.09.2014 (UNAUDITED)	30.09.2015 (UNAUDITED)	30.09.2014 (UNAUDITED)	31.03.2015 (AUDITED)	
	Income From Operations							
	(a) Net Sales (Net of Excise Duty)	9268.54	7982.83	8755.69	17251.37	15736.57	30945.8	
	(b) Other Operating Income	97.97	42.06	173.72	140.03	171.27	356.2	
	Total Income From Operations (Net)	9366.51	8024.88	8929.41	17391.40	15907.84	31302.1	
2	Expenses							
	a) Consumption of Raw Materials	3715.49	3483.87	4,219.51	7,199.36	6,796.19	13784.1	
	b) Purchase of Traded Goods	0.00	36.37	90.32	36.37	90.32	90.3	
	c) Changes in inventories of finished goods,							
	work in progress, Stock in Trade	-191.83	15.90	17.62	-175.93	285.73	248.2	
	d) Employee Benefit Expenses	564.07	482.58	409.13	1046.65	807.97	1736.0	
	e) Depreciation / Amortisation	157.67	135.22	118.48	292.88	231.41	507.8	
	f) Other Expenditure	2233.59	1577.41	1298.64	3811.00	2996.94	6823.9	
	Total Expenses	6478.99	5731.34	6153.69	12210.33	11208.55	23190.5	
	Profit From Operations Before Other Income &	2887.52	2293.55	2775.72	5181.07	4699.30	8111.5	
	Finance Cost& Exceptional Items (1-2)							
	Other Income	836.24	630.78	713.38	1467.02	1071.81	2135.0	
	Profit From Ordinary Activities	3723.76	2924.33	3489.10	6648.09	5771.11	10246.6	
	Before Finance Cost (3+4)							
	Finance Cost	416.24	291.18	251.17	707.42	475.15	1121.1	
	Profit From Ordinary Activities After Finance	3307.52	2633.15	3237.92	5940.67	5295.95	9125.4	
	Cost But Before Exceptional Items (5-6)							
1	Exceptional Items	-	-	-	-	-	-	
	Profit From Ordinary Activities Before Tax (7-8)	3307.52	2633.15	3237.92	5940.67	5295.95	9125.4	
0	Tax Expense (including Deferred Tax)	891.28	1092.90	1081.20	1984.18	1739.77	3123.9	
1	Net Profit After Tax For The Period (9 - 10)	2416.24	1540.25	2156.72	3956.49	3556.18	6001.5	
2	Paid - Up Equity Capital	1031.47	1031.47	1031.47	1031.47	1031.47	1031.4	
3	Reserves Excluding Revaluation Reserve (as Per Balance Sheet)	-		-	-	-	35787.1	
4	Basic And Diluted Eps (Not Annualised)	2.34	1.49	2.09	3.84	3.45	5.8	

	FAN	(ns. III Ldcs)							
	SR. No.	PARTICULARS	STANDALONE						
			QUARTER ENDED			SIX MONTHS ENDED		YEAR ENDED	
			30.09.2015 (UNAUDITED)	30.06.2015 (UNAUDITED)	30.09.2014 (UNAUDITED)	30.09.2015 (UNAUDITED)	30.09.2014 (UNAUDITED)	31.03.2015 (AUDITED)	
	A	Particulars of Shareholding							
	1	Aggregate of Non-promoter Shareholding							
		- No. of Shares (Face Value Rs. 1/- Each)	39899426	36156842	36156842	39899426	36156842	36156842	
		- Percentage of Shareholding (%)	38.68	35.05	35.05	38.68	35.05	35.05	
	2	Promoter and Promoter Group Shareholding							
		A) Pledge/ Encumbered							
		- No. of Shares (Face Value Re. 1/- Each)	-	-	-	-	-	ē	
		- Percentage of Shares (As % of the total Share							
		Holding of Promoter & Promoter Group)	-	-	-	-	-	-	
		- Percentage of Shares (As % of the total Share							
		Capital of The Company)	-	-	•	-	-	-	
		B) Non - Encumbered							
		- No. of Shares (Face Value Re. 1/- Each)	63247246	66989830	66989830	63247246	66989830	66989830	
		- Percentage of Shares (As % of the total Share							
		Holding of Promoter & Promoter Group)	100.00	100.00	100.00	100.00	100.00	100.00	
		- Percentage of Shares (As % of the total Share							
		Capital of The Company)	61.32	64.95	64.95	61.32	64.95	64.95	

SR. No.	PARTICULARS	Quarter Ended 30th September 2015
В	INVESTOR COMPLAINTS	
	Pending at the beginning of the quarter	-
	Received during the quarter	5
	Disposed off during the quarter	5
	REMAINING UNSOLVED AT THE END OF THE QUARTER	_

(Rs. in Lacs)

STATEMENT OF ASSETS AND LIABILITIES AS AT 30TH SEPTEMBER, 2015.

SR.	PARTICULARS	STANDALONE			
No.	PANTICULANS	Sep - 15	Mar - 15		
l ı. l	EQUITY AND LIABILITIES				
1	SHAREHOLDERS' FUNDS:				
	(i) Share Capital	1,031.47	1,031.47		
	(ii) Reserves and Surplus	40,175.08	35,787.14		
	(iii) Money received against share warrants	-	-		
	Sub-total - Shareholders' funds	41,206.55	36,818.61		
2	Non-Current liabilities				
	(i) Long term Borrowings	1,327.75	3,020.95		
	(ii) Deferred tax liabilities (Net)	799.07	715.30		
	(iii) Long term provisions	154.85	139.85		
	Sub-total - Non-current liabilities	2,281.67	3,876.10		
3	Current liabilities				
	(i) Short term Borrowings	2,765.88	2,837.62		
	(ii) Trade payables	6,031.68	5,046.72		
	(iii) Other current liabilities	5,028.35	3,913.46		
	(iv) Short term provisions	3,160.68	3,007.62		
	Sub-total -current liabilities	16,986.59	14,805.42		
	Total	60,474.81	55,500.13		
II.	ASSETS				
1	Non-current assets				
	(a) Fixed Assets	8,016.56	8,150.39		
	(b) Non-current Investments	2,059.37	1,922.63		
	(c) Long term loans and advances	11,285.53	10,135.08		
	(d) Other non current assets	-	43.26		
	Sub-total - Non-current assets	21,361.46	20,251.36		
2	Current assets				
	(a) Inventories	2,559.70	2,251.83		
	(b) Trade receivables	25,249.72	21,061.21		
	(c) Cash and Bank balances	5,722.02	4,736.77		
	(d) Short term loans and advances	4,393.76	6,133.62		
	(e) Other current assets	1,188.15	1,065.34		
Ш	Sub-total - Current assets	39,113.35	35,248.77		
	Total	60,474.81	55,500.13		

Notes:

- The company operates primarily in the Pharmaceutical Business and hence has only one reportable segment.
- The above results were reviewed by the audit committee & were there after approved by the board at its meeting held on November 09, 2015
- The statutory auditors have carried out a limited review of the results for the quarter ended September 30, 2015

4. Figures for the previous periods have been regrouped/rearranged wherever necessary.

FOR BLISS GVS PHARMA LIMITED SD/-S. N. KAMATH Managing director

Place : Mumbai Date : 09th November, 2015